O estudo da reprodução sexual de plantas e uma área de crescente interesse devido a importância de sementes e frutos em nossa dieta diária, ambos resultantes do desenvolvimento de partes do pistilo, apos fertilização. O objetivo deste trabalho foi caracterizar um novo gene F-box expresso no pistilo de N. tabacum. Proteínas F-box atuam na interação proteína-proteína, geralmente direcionando proteínas alvo para degradação pela via ubiquitina-proteassomo. Foram identificados cinco genes de função desconhecida que codificam putativas proteínas F-box, em duas bibliotecas de cDNAs de estigmas/estiletes de N. tabacum (DEPAOLI, 2006; QUIAPIM et al., 2009) previamente construídas em nosso laboratório. A expressão de cada um destes genes foi analisada nos diferentes órgãos de N. tabacum, por qRT-PCR. O clone 085H05 da biblioteca TOBEST (QUIAPIM et al., 2009) apresentou expressão preferencial nos órgãos florais. Este clone foi selecionado para uma caracterização funcional mais detalhada. O padrão de expressão deste gene foi avaliado no estigma/estilete durante os 12 estádios do desenvolvimento floral de N. tabacum (KOLTUNOW et al., 1990). O resultado revelou que sua expressão e regulada durante o desenvolvimento, atingindo o maior nível de expressão na antese (estádio 12). Isto sugere que este gene esteja envolvido no desenvolvimento do estigma/estilete. A sequência codificadora do gene correspondente a 085H05 foi determinada e, apos amplificação e clonagem, este gene foi denominado S/S_F-box (Stigma/Style_F-box). Para compreender a função da proteína de S/S_F-box, plantas transgênicas de superexpressao e de silenciamento (por RNAi) deste gene foram geradas. As plantas de RNAi apresentaram o estilete e o ovário reduzidos quando comparados ao controle SR1. Em concordância, as plantas de superexpressao produziram flores com o estilete mais alongado do que o controle, alem do estigma e do ovário de maior tamanho. Altas concentrações de exudato foram observadas na superfície do estigma destas plantas, a partir do estádio 7 tardio. No controle SR1, concentrações equivalentes apenas são observadas nos estádios finais do desenvolvimento. Os fenótipos observados nas plantas transgênicas sugerem que a proteína codificada por S/S_F-box esteja envolvida com o desenvolvimento do pistilo e com o controle do tamanho deste órgão. Adicionalmente, as plantas de RNAi apresentaram o fenótipo de perda da dominância apical. Os níveis de expressão do gene S/S_F-box foram avaliados em plantas que tiveram aumento na produção de auxina no estigma/estilete (plantas STIG1prom::iaaM), revelando que este gene não e regulado, a nível transcricional, por este hormônio. Experimentos de localização subcelular, realizados por expressão transitória da sequência de S/S_F-box fusionada a sequência dos genes repórteres GFP e YFP (S/S_F-box::GFP; S/S_F-box::YFP), indicaram que a proteína S/S_F-box esta localizada no citoplasma e no núcleo celular. Adicionalmente, foi realizado o screening de uma biblioteca de cDNAs de estigma/estilete, construída no sistema de duplo-hibrido, para investigar proteínas candidatas a interagirem com a proteína de S/S_F-box. Os resultados indicaram interação da proteína S/S_F-box com SKP1, confirmando a participação de S/S_F-box no complexo SCF, que promove a degradação de proteínas alvo pela via ubiquitina-proteassomo. Duas proteínas candidatas a alvo foram identificadas: os fatores de transcrição VOZ1 e SIP1, ambos envolvidos com a proliferação celular. Em suma, e possível propor que a proteína codificada por S/S_F-box tenha função relacionada a proliferação celular e ao desenvolvimento dos órgãos vegetais, incluindo o pistilo. / The study of sexual reproduction in plants is an area of increasing interest due to the importance of seeds and fruits in our daily diet, both resulting from the development of parts of the pistil, after fertilization. The aim of this study was to characterize a new F-box gene expressed in the N. tabacum pistil. F-box proteins act in protein-protein interactions, generally directing target proteins to degradation via ubiquitin-proteasome. Five genes of unknown function coding for putative F-box proteins were identified at two cDNAs libraries from N. tabacum stigmas/styles (DEPAOLI, 2006; QUIAPIM et al., 2009), previously constructed in our laboratory. The expression of each of these genes was analyzed in the different N. tabacum organs, by qRT-PCR. The 085H05 clone from the TOBEST library (QUIAPIM et al., 2009) showed preferential expression in floral organs. This clone was select for a more detailed functional characterization. The expression pattern of this gene was evaluated in the stigma/style during the 12 N. tabacum flower developmental stages (KOLTUNOW et al., 1990). The result revealed that its expression is regulated during development, reaching the highest expression level at anthesis (stage 12). It suggests that this gene is involved in the stigma/style development. The coding sequence of the gene corresponding to 085H05 was determined and, after amplification and cloning, the gene was named S/S_F-box (Stigma/Style_F-box). To understand the S/S_F-box protein function, transgenic plants either overexpressing or silencing (by RNAi) the S/S_F-box gene were generated. The RNAi plants showed reduced style and ovary when compared to the control SR1. In accordance, the overexpressing plants produced flowers with a style more elongated than the control, besides an ovary and a stigma of larger size. High concentrations of exudate were observed on the stigma surface of these plants, since the later stage 7. In the control SR1, equivalent concentrations are only observed at the later stages of development. The phenotypes observed in the transgenic plants suggest that the protein encoded by S/S_F-box is involved with pistil development and with the control of pistil size. Additionally, the RNAi plants showed the phenotype of loss of apical dominance. The expression levels of the S/S_F-box gene were evaluated in plants with increased auxin production in the stigma/style (plants STIG1prom::iaaM), showing that this gene is not transcriptionally regulated by this hormone. Subcellular localization experiments, carried out by transient expression of the S/S_F-box sequence fused to the reporter genes GFP and YFP V (S/S_F-box::GFP; S/S_F-box::YFP), showed that the S/S_F-box protein is localized in the cytoplasm and in the nucleus. Additionally, the screening of a stigma/style cDNA library constructed on the yeast two hybrid system was performed, to investigate candidate proteins for S/S_F-box protein interaction. The results indicated interaction between S/S_Fbox and the SKP1 protein, confirming the involvement of the S/S_F-box protein in the SCF complex, which promotes degradation of target proteins via ubiquitin-proteasome. Two candidates for target proteins were identified: the transcription factors VOZ1 and SIP1, both involved in cell proliferation. In summary, it is possible to propose that the protein encoded by S/S_F-box has functions related to cell proliferation and organ development, including the pistil.

Previously it was demonstrated that biliary excretion of a single dose of [14C]dieldrin or [3H]7, 12-dimethylbenz/alanthracene (DMBA) was stimulated up to 700% and 300%, respectively, in rainbow trout fed 0.3-0.4 mg dieldrin/kg/d for 9-12 wk. This was not explained by increased activities of hepatic microsomal xenobiotic-metabolizing enzymes or increased amounts of any of six cytochrome P-450 isozymes quantitated by Western blots. It was hypothesized that stimulated excretion was explained by induction of (1) cytosolic binding proteins that facilitated intracellular trafficking of DMBA to sites of metabolism, or (2) ATP-dependent proteins that transport xenobiotic metabolites from liver to bile. Binding of 15 and 60 nmol [3H]DMBA/mg protein increased about 200% in hepatic cytosol from dieldrin-fed fish. A 50-fold molar excess of unlabeled DMBA reduced binding of 15 nmol [3H]DMBA/mg protein (nonspecific binding) by the same amount in cytosol from control and dieldrin-fed fish, indicating that dieldrin induced specific binding. Liver sections from control and dieldrin-fed fish were treated with multidrug resistance (MDR) protein monoclonal antibodies C494, C219, and JSB-1, and polyclonal antibody MDR Ab-1. There were no marked differences in optical densities of immunohistochemical staining near bile canaliculi of control and dieldrin-fed fish. Induction of xenobiotic binding capacity in cytosol of dieldrin-fed rainbow trout at least partially explained altered DMBA disposition in fish pretreated with this cyclodiene insecticide.

No description available.

<p>U ovoj doktorskoj disertaciji prikazani su rezultati istraživanja 15&nbsp;vrsta&nbsp; biljaka&nbsp; koje&nbsp; pripadaju&nbsp; rodovima <em>Rumex,&nbsp; Polygonum,&nbsp;Bistorta,&nbsp; Persicaria i&nbsp; Fagopyrum,</em>&nbsp; podfamilije&nbsp; Polygonoideae,&nbsp;familije&nbsp; Polygonaceae,&nbsp; sakupljenih&nbsp; na&nbsp; teritoriji&nbsp; centralnog&nbsp; i&nbsp;zapadnog &nbsp;Balkana u periodu od 2009-2011. godine. Sprovedena&nbsp;istraživanja&nbsp; su&nbsp; se&nbsp; odvijala&nbsp; u&nbsp; dva&nbsp; pravca:&nbsp; fitohemijska&nbsp; i&nbsp;biohemijsko-biolo&scaron;ka&nbsp; ispitivanja.&nbsp; Predmet&nbsp; analiza&nbsp; bili&nbsp; su&nbsp;ekstrakti&nbsp; herbi&nbsp; i&nbsp; rizoma&nbsp; ispitivanih&nbsp; biljaka.&nbsp; Fitohemijska&nbsp;ispitivanja&nbsp; obuhvatila&nbsp; su,&nbsp; pored&nbsp; spektrofotometrijskog&nbsp;određivanja&nbsp; ukupnih&nbsp; fenola,&nbsp; ukupnih&nbsp; flavonoida&nbsp; i&nbsp; ukupnih&nbsp;antrahinonskih jedinjenja, i određivanje sadržaja 51 komponente&nbsp;iz standardne sme&scaron;e različitih klasa fenolnih jedinjenja LC-MSMS&nbsp; metodom,&nbsp; odnosno &nbsp;hromatografsko&nbsp; profilisanje&nbsp; ekstrakata&nbsp;LC-DAD-MS&nbsp; metodom.&nbsp; Odabirom&nbsp; nekoliko&nbsp; različitih&nbsp; model&nbsp;sistema&nbsp; za&nbsp; merenje&nbsp; antioksidantne&nbsp; aktivnosti&nbsp; (neutralizacija&nbsp;DPPH&nbsp; radikala,&nbsp; redoks&nbsp; kapacitet&nbsp; -&nbsp; FRAP&nbsp; test,&nbsp; skevindžer&nbsp;aktivnost&nbsp; prema&nbsp; superoksidanjon&nbsp; radikalu,&nbsp; NO&nbsp; radikalu&nbsp; i&nbsp; OH&nbsp;radikalu,&nbsp; kao&nbsp; i&nbsp; inhibicija&nbsp; lipidne&nbsp; peroksidacije)&nbsp; procenjen&nbsp; je&nbsp;antioksidantni&nbsp; potencijal&nbsp; ekstrakata,&nbsp; dok&nbsp; je&nbsp; za&nbsp; procenu&nbsp; njihove&nbsp;antiinflamatorne&nbsp; aktivnosti&nbsp; kori&scaron;ćen&nbsp; potencijal&nbsp; inhibicije&nbsp;biosinteze medijatora inflamacije u humanim trombocitima (kao&nbsp;model&nbsp; sistemu).&nbsp; Mikrobiolo&scaron;ka&nbsp; ispitivanja&nbsp; su&nbsp; obuhvatila&nbsp;određivanje&nbsp; potencijala&nbsp; ovih&nbsp; vrsta&nbsp; u&nbsp; inhibiciji&nbsp; rasta&nbsp; serije&nbsp; gram&nbsp;pozitivnih i gram negativnih sojeva batkerija. Konačno, urađena&nbsp;je&nbsp; analiza&nbsp; korelacije&nbsp; hemijskog&nbsp; sastava,&nbsp; biolo&scaron;ke&nbsp; aktivnosti&nbsp; i&nbsp;pripadnosti taksonomskim grupama.</p> / <p>Phytochemical&nbsp; and&nbsp; biochemical&nbsp; analysis&nbsp; of&nbsp; herbal&nbsp; and&nbsp; root&nbsp;ethanol&nbsp; extracts&nbsp; of&nbsp; 15&nbsp; species&nbsp; belonging&nbsp; to&nbsp; different&nbsp; genera&nbsp;(<em>Rumex,&nbsp; Polygonum,&nbsp; Bistorta,&nbsp; Persicaria and&nbsp; Fagopyrum</em>)&nbsp; of&nbsp;subfamily&nbsp; Polygonoideae,&nbsp; was&nbsp; examined.&nbsp; Phytochemical&nbsp;characterization&nbsp; included&nbsp; spectrophotometric&nbsp; determination&nbsp; of&nbsp;total&nbsp; phenolic,&nbsp; total&nbsp; flavonoids&nbsp; and&nbsp; total&nbsp; anthraquinone&nbsp; contents,&nbsp;quantification&nbsp; of&nbsp; 51&nbsp; secondary&nbsp; metabolites&nbsp; by&nbsp; LC/MS/MS&nbsp;analysis&nbsp; and&nbsp; chromatographic&nbsp; fingerprinting by&nbsp; LC/DAD/MS&nbsp;technique,&nbsp; of&nbsp; prepared&nbsp; extracts.&nbsp; The&nbsp; antioxidant&nbsp; activity&nbsp; was&nbsp;evaluated&nbsp; by&nbsp; measuring&nbsp; ferric&nbsp; reducing&nbsp; ability&nbsp; (FRAP)&nbsp; of&nbsp; the&nbsp;extracts and their radical scavenging capacity towards DPPH, OH,&nbsp;NO and O₂^{&ndash;&nbsp;}radicals, and inhibition of lipid peroxidation). Antiinflammatory activity was evaluated by LC/MS/MS monitoring of&nbsp;selected&nbsp; metabolites&nbsp; (12-(S)-HHT,&nbsp; 12(S)-HETE,&nbsp; PGE_2&nbsp;,&nbsp; PGF_2&alpha;,&nbsp;and TXB₂) formed in cyclooxygenase and lipoxygenase pathways&nbsp;of arachidonic acid metabolism. Human platelets were used as a&nbsp;source&nbsp; of&nbsp; enzymes,&nbsp; while&nbsp; inflammation&nbsp; was&nbsp; induced&nbsp; by&nbsp;calcimycin. The antibacterial activity of prepared&nbsp; extracts against&nbsp;nine&nbsp; bacterial&nbsp; strains&nbsp; was&nbsp; evaluated&nbsp; by&nbsp; microtiter&nbsp; assay&nbsp; with&nbsp;resazurin as a colorimetric growth indicator.</p>

L’ostéonécrose (ON) et les fractures (FR) sont des complications qui prennent de plus en plus place dans le traitement pédiatrique de la leucémie aiguë lymphoblastique (LAL). L’ON peut être causée par différents facteurs, dont principalement l’utilisation de glucocorticoïdes. Les glucocorticoïdes sont administrés lors du traitement de la leucémie dans le but d’initier l’apoptose des cellules malignes tout en ayant un effet anti-inflammatoire. Cependant, l’utilisation de ces corticostéroïdes comprend des effets secondaires sérieux, notamment le développement d’ostéonécrose. Des variantes génétiques peuvent mettre certains patients plus à risque que d’autres. Plusieurs gènes ont déjà été signalés comme régulés par les actions glucocorticoïdes (GC). Les variations génétiques présentes dans les régions régulatrices de ces gènes peuvent affecter leur fonctionnement normal et, en fin de compte, de déterminer un risque accru de développer l’ON associé au traitement contre la leucémie. Pour cette raison, plusieurs polymorphismes ont été identifiés et étudiés dans la cohorte QcALL de Ste-Justine, concernant les gènes suivants : ABCB1, ACP1, BCL2L11, NFKB1, PARP1, et SHMT1. Ces gènes jouent majoritairement un rôle dans les mécanismes d’action des glucocorticoïdes, mais quelques-uns ont plutôt un effet direct sur le développement d’ostéonécrose. Nos recherches ont démontré une corrélation entre ces polymorphismes et l’apparition d’ostéonécrose chez les patients de la cohorte QcALL, traités aux glucocorticoïdes. L'incidence cumulative de l'ostéonécrose a été évaluée rétrospectivement chez 305 enfants atteints de la leucémie qui ont subi un traitement à l’hôpital Ste-Justine selon les protocoles DFCI de Boston (87-01, 91-01, 95-01 et 2000-01). Parmi les huit polymorphismes de BCL2L11 étudiés, les 891T> G (rs2241843) et 29201C> T (rs724710) ont été significativement associés à ON (p = 0.01 et p = 0.03, respectivement). L'association du polymorphisme 891T> G a été modulée par le type de corticostéroïde (CS), l’âge, le sexe et le groupe à risque (p ≤ 0,05). Le polymorphisme 29201C> T était particulièrement apparent chez les patients à haut risque (p = 0,003). La même étude était conduite en parallèle sur des patients de la cohorte DFCI de Boston (N = 192), et montrait des résultats significatifs pour les polymorphismes étudiés. En conclusion, les résultats de cette étude permettront de confirmer l’association de ces polymorphismes au développement d’ON chez les patients de LLA traités aux GC. / Osteonecrosis (ON) and fractures (FR) are complications that take place in the treatment of children acute lymphoblastic leukemia (cALL). They can be caused by various factors, mainly using glucocorticoids. The corticosteroids, dexamethasone (DXM) and prednisone (PDN) are administered during the treatment of leukemia to initiate apoptosis of malignant cells; while having an anti-inflammatory effect. However, the use of these corticosteroids has severe side effects, including the development of osteonecrosis. Moreover, some patients develop resistance to treatment, and are at risk of developing side effects. The genetic variants predispose some patients at higher risk than others. Several genes have been previously reported as up- or down regulated by the GCs actions. The genetic variations present in gene coding or regulatory regions can affect their function and ultimately determine an increased risk of developing ON associated to ALL therapy. Therefore, we investigated the association between several single nucleotide polymorphisms (SNPs) in six candidate genes: BCL2L11, NFKB1, PARP1, ABCB1, ACP1, and SHMT1. These genes play a role in the mechanisms of action of glucocorticoids, but some have more of a direct effect on the development of osteonecrosis. Our research has shown a correlation between these polymorphisms and the occurrence of osteonecrosis in patients in the QCALL cohort, treated with glucocorticoids. Cumulative incidence of osteonecrosis was assessed retrospectively in 305 children with ALL who underwent treatment with DFCI protocols (87-01, 91-01, 95-01 and 2000-01) in childhood ALL cohort from Quebec (QcALL). Among the eight tag BCL2L11 polymorphisms studied the 891T>G (rs2241843) and 29201C>T (rs724710) were significantly associated with ON (p = 0.01 and p = 0.03, respectively). Association of 891T>G polymorphism was modulated by type of corticosteroid (CS), age, sex and risk group (p ≤ 0.05 and that of 29201C>T was particularly apparent among high risk (p = 0.003) patients. These polymorphisms have shown significant ON association in several QcALL risk groups, mainly in corticosteroid groups, age < 10 years, and high risk (HR) group. Furthermore, the same study was conducted in parallel with patients in the replication (DFCI) cohort (N = 192), and we showed significant genetic association results for all studied polymorphisms. In conclusion, this study identifies that some ALL children have a high incidence of ON during the treatment that is highly associated with polymorphisms in different genes regulated by corticosteroids and ALL prognostic factors.